Subsidiary Company of Bharat Parenterals Limited has received the Establishment Inspection Report from the U.S FDA.

Bharat Parenterals' subsidiary Innoxel Lifesciences has received the Establishment Inspection Report (EIR) from the U.S. FDA for its finished dosage manufacturing facility in Vadodara, Gujarat. This follows a successful U.S. FDA inspection conducted from April 28 to May 2, 2025. With the EIR, the facility has also been accepted for commercial operations for the products under inspection. The facility manufactures Liquid Injectables and Oral Liquids, and this clearance enhances the company's ability to supply pharmaceutical products to regulated markets like the U.S. and EU.